SANGAMO THERAPEUTICS, INC reported year ended December 31, 2025 results: revenue $39.6 million, net income $122.9 million, EPS $0.44 per share.
“For the year ended December 31, 2025, consolidated net loss was $122.9 million, or $0.44 per share, compared to consolidated net loss of $97.9 million, or $0.49 per share, for the year ended December 31, 2024. Revenues Revenues for the fourth quarter ended December 31, 2025 were $14.2 million, compared to $7.6 million for the same period in 2024. The increase of $6.6 million in revenues was primarily attributable to $6.0 million in revenue relating to Pfizer’s exercise of its option to obtain a license pursuant to the terms of the 2008 licensing agreement for certain zinc finger modified cell lines, an increase of $1.0 million in revenue relating to our collaboration agreement with Astellas, and $0.4 million in revenue from research services relating to our capsid license agreement with Lilly, partially offset by $0.8 million in revenue relating to our collaboration agreement with Genentech recognized in 2024. Revenues were $39.6 million in 2025, compared to $57.8 million in 2024. The”
Earnings Releases
SANGAMO THERAPEUTICS, INC reported fourth quarter ended December 31, 2025 results: revenue $14.2 million, net income $37.4 million, EPS $0.11 per share.
“to consolidated net loss of $97.9 million, or $0.49 per share, for the year ended December 31, 2024. Revenues Revenues for the fourth quarter ended December 31, 2025 were $14.2 million, compared to $7.6 million for the same period in 2024. The increase of $6.6 million in revenues was primarily attributable to $6.0 million in revenue relating to Pfizer’s”
Material Agreements
SANGAMO THERAPEUTICS, INC entered into Underwriting Agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC valued at approximately $25.0 million (effective 2026-02-03).
“On February 3, 2026, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC”
Listing & Compliance Notices
SANGAMO THERAPEUTICS, INC received a nasdaq extension granted notice regarding minimum bid price (rules 5810(c)(3)(A)).
“October 29, 2025, Sangamo Therapeutics, Inc. (the “Company”) received a letter (the “Extension Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension, or until April 27, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to April 27, 2026, the bid price of the Company’s common”
Listing & Compliance Notices
SANGAMO THERAPEUTICS, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).
“April 30, 2025 from the Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of the Common Stock, for the preceding 30 consecutive business days, the Company was not in compliance with the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 days, or until October 27, 2025, to regain compliance with the Minimum Bid Price Requirement. The Company intends to cure the Minimum Bid Price Requirement by April 27, 2026, however if the Company does not regain compliance with the Minimum Bid Price Requireme”
Earnings Releases
SANGAMO THERAPEUTICS, INC reported financial results for the quarter ended March 31, 2024.
“On May 9, 2024, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the quarter ended March 31, 2024 (the “Press Release”).”
Listing & Compliance Notices
SANGAMO THERAPEUTICS, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“April 24, 2024, Sangamo Therapeutics, Inc. (the “Company”) received a deficiency notice, or the Notice, from the Listing Qualifications Staff, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that, for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market. In accordance with Nasd”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.